TY  - JOUR
TI  - Improvement of Work Productivity and Quality of Life 
with Anti-Tumor Necrosis Factor Treatment Used in 
Crohn’s Disease in Routine Clinical Practice in Turkey
AB  - Background: Patients with Crohn’s disease experience major deterioration in work productivity and quality of life. We aimed to provide 
the long-term effects of anti-tumor necrosis factor agents on work productivity and activity impairment and quality of life in patients 
with Crohn’s disease using the Inflammatory Bowel Disease Questionnaire and the Short-Form Health Survey-36.
Methods: Patients with Crohn’s disease and initiated an anti-tumor necrosis factor treatment were included and followed up for 
12 months in this observational study.
Results: A total of 106 patients were included in this study, and 64.2% of the patients were males. Mean [± standard deviation] age 
was 36.8 [± 10.9] years. At baseline, mostly perianal fistulas [65.7%] were observed [n = 23]. Intestinal stenosis was detected in 34.9% 
of the patients [n = 37], and most of the stenosis was located in the ileum [70.6%] followed by the colon [20.6%]. Extraintestinal symptoms were observed in 24 patients [22.6%]. Most frequent extraintestinal symptom was arthritis with 71.4% [n = 15]. Mean time from 
first symptom to initiation of anti-tumor necrosis factor treatment was 6.3 [± 5.0] years. Improvements in work productivity and activity impairment scores throughout 12 months were −24.1% [P = .003] for work time missed, −18.0% [P = .006] for impairment at work, 
−8.5% [P = .160] for overall work impairment, and −17.0% [P < .001] for daily activity impairment. Similarly, significant improvements [P 
< .001] were detected in all components of the Inflammatory Bowel Disease Questionnaire when compared to baseline. Statistically significant improvements [P < .05] were detected for all components of Short-Form Health Survey-36 except for mental health [P = .095].
Conclusion: Our study indicates the significant improvement in work productivity and activity impairment and quality of life of patients 
with Crohn’s disease who receive long-term anti-tumor necrosis factor treatment
AU  - Basaranoglu, Metin
AU  - Akpınar, Hale
AU  - Akyuz, Filiz
AU  - Sezgin, Orhan
AU  - Celik, Aykut Ferhat
AU  - Hamzaoglu, Hulya
AU  - cekic, cem
AU  - Senturk, Omer
AU  - Toruner, Murat
AU  - GOKTURK, HUSEYIN SAVAS
AU  - ATUG, OZLEN
AU  - Tezel, Ahmet
AU  - TEKİN, Fatih
AU  - Kav, Taylan
DO  - 10.5152/tjg.2022.21868
PY  - 2022
JO  - Turkish Journal of Gastroenterology
VL  - 33
IS  - 5
SN  - 1300-4948
SP  - 406
EP  - 413
DB  - TRDizin
UR  - http://search/yayin/detay/532767
ER  -